Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.57 |
| ▸ | PI4KA | P42356 | 2/20 | 0.57 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.57 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.57 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.57 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.57 |
| ▸ | GAPDH | P04406 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | STAT6 | P42226 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.57 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18874985 | 1.00 | ADORA2A (0.71) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL9395400 | 1.00 | ADORA2A (0.71) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL29722607 | 1.00 | ADORA2A (0.71) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL9395384 | 1.00 | ADORA2A (0.71) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| Phosphoric Acid SCHEMBL21489151 | 0.95 | ADORA2A (0.65) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| Phosphoric Acid SCHEMBL21465116 | 0.95 | ADORA2A (0.65) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL31725339 | 0.89 | ADORA2A (0.62) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL3437115 | 0.88 | ADORA2A (0.54) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL1374258 | 0.86 | ADORA2A (0.67) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL1374261 | 0.86 | ADORA2A (0.67) | ADORA2AADORA3PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12083185-B2 | Small polymeric carriers for delivery of agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-09-10 | — | — | US | claimed |
| WO-2021224646-A1 | METHOD FOR THE TREATMENT OF RNA VIRUS INVOLVED DISEASES | TURNSOLE BIOLOGICS LLC. (HU) | 2021-11-11 | — | — | WO | claimed |
| US-20210330808-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | claimed |
| EP-3863609-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | University of Pittsburgh - Of the Commonwealth System of Higher Education (US) | 2021-08-18 | — | — | EP | claimed |
| CN-112823000-A | Small polymer carriers for agent delivery | 联邦高等教育系统匹兹堡大学 | 2021-05-18 | — | — | CN | claimed |
| US-12466849-B2 | Anti-viral and anti-tumoral compounds | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-11-11 | — | — | US | disclosed |
| US-20250281574-A1 | COMPOSITIONS AND METHODS FOR TREATING COMPLICATIONS OF VIRAL INFECTIONS AND OTHER RESPIRATORY DISORDERS | XEQUEL BIO INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250161334-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250057975-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2025-02-20 | — | — | US | disclosed |
| US-12226478-B2 | Method of treating, reducing, or alleviating a medical condition in a patient | PEYMAN GHOLAM A (US) | 2025-02-18 | — | — | US | disclosed |
| US-12083185-B2 | Small polymeric carriers for delivery of agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230072222-A1 | ANTI-VIRAL AND ANTI-TUMORAL COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2023-03-09 | — | — | US | disclosed |
| WO-2022165386-A1 | LNP AND LMP DELIVERY OF ANTIVIRAL NUCLEOTIDE 5'-PHOSPHATES | VIRBIS LLC (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220202933-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2022-06-30 | — | — | US | disclosed |
| WO-2022038539-A2 | ANTI-VIRAL AND ANTI-TUMORAL COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-02-24 | — | — | WO | disclosed |
| WO-2021224646-A1 | METHOD FOR THE TREATMENT OF RNA VIRUS INVOLVED DISEASES | TURNSOLE BIOLOGICS LLC. (HU) | 2021-11-11 | — | — | WO | disclosed |
| US-20210330808-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | disclosed |
| EP-3863609-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | University of Pittsburgh - Of the Commonwealth System of Higher Education (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-112823000-A | Small polymer carriers for agent delivery | 联邦高等教育系统匹兹堡大学 | 2021-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072222-A1 | ANTI-VIRAL AND ANTI-TUMORAL COMPOUNDS | EIF2AK2, NSUN2, SARS1 | ADORA2A 3677/4885ADORA3 4073/4885PI4KA 1552/4885 |
| US-12466849-B2 | Anti-viral and anti-tumoral compounds | EIF2AK2, NSUN2, SARS1 | ADORA2A 3677/4885ADORA3 4073/4885PI4KA 1552/4885 |
| US-20250057975-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | CD44, PGF, SLC46A1 | ADORA2A 3965/4885ADORA3 4137/4885PI4KA 2734/4885 |
| US-12083185-B2 | Small polymeric carriers for delivery of agents | CD44, PGF, SLC46A1 | ADORA2A 3965/4885ADORA3 4137/4885PI4KA 2734/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | ADORA2A 2769/4885ADORA3 4081/4885PI4KA 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.